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Figure – Abstract 269 – Risk factors and survival after LT in FAP patients.
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Protective effect of saffron extracts against doxorubicin cardiotoxicity
Nathalie Chahine (1), Laurent Duca (2), Laurent Martiny (2), Ramez Chahine (1) 
(1) Université Libanaise, Faculté des sciences médicales, Beyrouth, Liban – (2) 
Université de Reims Champagne Ardenne, Faculté des sciences, Reims, France
Doxorubicin (DOX) continues to be used extensively to treat various malignancies, 
yet the usefulness of this drug is limited by its cardiotoxicity. Subcellular changes 
leading to this toxicity are suggested to be mediated through an increase in free 
radicals and lipid peroxidation. 
The aim of the present study was to assess whether a 6 weeks supplement with 
saffron (SAF), a natural antioxidant, in rabbits might prevent the cardiotoxicity of 
DOX treatment. 40 adult male rabbits (Oryctolagus cunnilicus) were used in this study. 
They were randomized into 4 groups (n=10 /group). Group I (control) without 
any treatment. Group II received orally an optimal dose of saffron extracts (5 mg/
kg bw) daily for 6 weeks. Group III received a single IP dose of DOX weekly for 
4 weeks at a dose of (2.5 mg/kg bw) starting from the 3rd week. Group IV received 
SAF as in group II and DOX injection as in group III. One week after the end of 
DOX treatment, the surviving rabbits were sacrifi ced and their hearts were perfused 
on a Langendorff mode and subjected to a 30 min period of global ischemia followed 
by 30 min reperfusion. 
The results were as follows: saffron supplementation in DOX treated rabbits 
signifi cantly 1) reduced mortality (3 in DOX group III and 1 in group IV); 2) improved 
cardiac function recovery and reduced the incidence of arrhythmias at reperfusion; 3) 
reduced infarct side; 4) increased the activity of myocardial glutathione peroxidase 
(GPx) and reduced malondialdehyde content; 5) reduced damage and necrosis of 
cardiomyocytes after histopathological examination. 
In conclusion, this study demonstrates that saffron supplementation is able to 
limit DOX cardiotoxicity in isolated rat hearts submitted to a sequence of ischemia/
reperfusion.
 TOPIC 19 – Heart failure, 
cardiomyopathies – A
April 18th, Thursday 2013
269
Cardiac infi ltration is an independent risk factor of survival after liver 
transplantation in transthyretin amyloidosis
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France – (4) EA4046 – réanimation médicale – CHU de Bicêtre, Kremlin Bicêtre, 
France – (5) CHU Bichat Claude Bernard, médecine nucléaire, Paris, France 
– (6) Centre de référence des neuropathies familiales amyloïdes – CHU de Bicêtre, 
APHP, Kremlin Bicêtre, France
Background: Hereditary transthyretin amyloidosis (HA-TTR) is an autosomic 
dominant disease caused by mutated TTR, leading to both polyneuropathy and infi ltrative 
cardiomyopathy. By removing the main source of mutated TTR, liver transplantation 
(LT) improves patient’s prognosis. Our aim was to document the infl uence of cardiac 
and neurological status on survival after LT. 
Method: In HA-TTR patients having been liver-transplanted since 1993 in our 
French reference center, survival was analyzed by using a multivariate Cox model 
including age, sex, mutation type and preoperative characteristics including neurological 
Norris score, relative wall thickness (RWT) measured by echocardiography and 
invasive intraventricular pressures. ROC curves (5-year survival) were also obtained.
Results: The present interim analysis included 155 HA-TTR patients (46±13 
yrs, 67% Val30Met mutation). During a mean follow-up of 77±56 months, 43 patients 
died (1-year survival 92±2%, 5-year survival 79±4%, 10-year survival 66±5%). Non 
survivors were older, mostly males, with less frequent Val30Met mutation, lower 
Norris score, thicker cardiac walls and higher LV and RV pressures. Multivariate 
analysis indicated that RWT and Norris score were independent predictors of death 
(RWT; HR=87. 95%IC: 8-900, p=0.0002; Norris score: HR=0.94, 95%IC: 0.9-0.98, 
p=0.002) while age, sex and mutation type were not. The 5-year survival following 
LT was 23±12% for patients with RWT>0.526 and Norris score <86% vs 98±2% for 
patients with RWT<0.526 and Norris score >86% (log rank test p<0.0001).
Conclusion: Cardiac infi ltration and the severity of polyneuropathy were 
independent risk factors of poor survival in liver-transplanted patients with HA-TTR.
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each group). Cardiotoxicity was assessed using echocardiography, myocardial 
expression of natriuretic peptides (ANP, BNP) and beta-myosin heavy chain. 
Oxidative stress was assessed by electron spin resonance spectroscopy (ESR) 
using a spin probe (CMH hydroxylamine).Iron content was evaluated by atomic 
absorption spectrometry.
Results: At the end of the treatments, there was a signifi cant fall in left ventricular 
ejection fraction (LVEF) in animals treated with DOX alone (DOX group) and in 
animals with prior IO treated with DOX (IRON-DOX group) as compared to their 
baseline values. LVEF impairment in IRON-DOX mice was similar to that in DOX 
mice (51±5% vs 44±7%). Unlike the DOX group, there was no increase in left 
ventricular diameter and ANP mRNA cardiac levels compared to baseline values 
in IRON-DOX group. However, the IRON-DOX group had a signifi cantly higher 
myocardial expression of BNP than the DOX group. IO alone (IRON) resulted in 
cardiac hypertrophy as assessed by an increase in LV weight (+25%). The CP• signal 
intensity was signifi cantly higher in the IRON group than in the control group, and 
higher in the IRON-DOX group than in the DOX group. 
Conclusions: IO did not result in a signifi cant increase in DOX cardiotoxicity in 
mice. Conversely, our results suggest the role of prior chronic oxidative stress induced 
by IO could mitigate acute DOX cardiotoxicity. 
400
Effects at 12 months of alcohol septal ablation on diastolic dysfunction in 
patients with hypertrophic obstructive cardiomyopathy
Minh Tam Le (1), Remi Choussat (2), Richard Isnard (2), Michel Komajda (2), 
Philippe Charron (3) 
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Background: Alcohol septal ablation (ASA) is an alternative therapy to septal 
myomectomy or dual chamber pacemaker for treatment of symptomatic hypertrophic 
obstructive cardiomyopathy (HOCM). Effi ciency of ASA on left ventricle (LV) 
diastolic dysfunction, a major determinant of symptoms and outcome, has been 
poorly described until now.
Objective: To evaluate the procedural and one-year clinical and echocardiographic 
outcomes, with a specifi c focus on diastolic dysfunction, in patients with HOCM 
treated by ASA.
Methods: A prospective observational study was conducted in a single institution 
(Institute of Cardiology, Pitié Salpêtriere hospital, Paris) for consecutive patients 
undergoing ASA. All patients had clinical (NYHA class, cardiovascular event) biological 
(BNP) and echographic monitoring during the follow-up (3, 6 and 12 months). Data 
were analysed using the paired t test (α=0.05).
Results: 23 patients were included (12 men and 11 women) with a mean age of 
60 y. For all patients, a single septal branch was treated using a total of 1 to 2.5 mL 
of ethanol (mean 1.80) in 2 to 5 injections (mean 3.80). Results of BNP, E/A, E/Ea, 
DT and LVOT (LV outfl ow tract) were summarize in Table 1. There was a signifi cant 
decrease of LVOT gradient (58.4 to 34.9, p<0.01) and inducible LVOT gradient (123.7 
to 97.7 mmHg, p<0.01) at 12th month. Three months after ablation, E/A ratio decreased 
from 1.51 to 1.26 (p=0.007). There was a signifi cant decrease of BNP (1046 vs 314 ng/l 
at 6 months, p=0.004) resulting in a clinical improvement (median NYHA at baseline 
was 3, median NYHA at 3, 6 and 12 months was 2). 3 complications (ventricular 
arrhythmias, aortic valve replacement for shredding of aortic cups, Scarpa hematoma) 
occurred on peri-procedural survey and 2 non-cardiac deaths (mesenteric ischemia 
and ischemic stroke) occurred during the follow-up.
Conclusion: ASA appears as an effective treatment of HOCM at 12 months, 
regarding effect on obstruction but also on LV diastolic function. 
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Prevalence and severity of sleep apnoea syndromes in cardiac amyloidosis 
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Background: Cardiac diseases are associated with a high prevalence of sleep 
apnoea syndrome (SAS) particularly in heart failure. Two types of SAS are known: 
central or obstructive. Heart failure can occur in patients with primary systemic 
amyloidosis (AL), senile systemic amyloidosis (SSA), and Transthyretin-Related 
Amyloidosis (TTR). There is no data about prevalence and severity of sleep disordered 
breathing in cardiac amyloidosis.
Aims: To assess the prevalence and severity of SAS in cardiac amyloidosis.
Methods: Patients prospectively referred in our cardiology department for 
cardiac amyloidosis underwent polygraphy to diagnose sleep apnoea syndrome (SAS) 
between 2010 and 2012. SAS was defined as an apnoea-hypopnoea index greater or 
equal to 5 events/h.
Results: Thirty fi ve patients were included, of whom 15 had AL, 9 FAP and 11 
SSA. Mean age, left ventricular ejection fraction, and body mass index of the overall 
cohort were respectively 75±12 years, 45±13% and 24±4 kg/m2. The prevalence of 
SAS was 86%. 29% of syndromes were classified as central and 57% as obstructive. 
The mean apnoea hypopnoea index was 22±14 events/h and was superior to 30 events/h 
in 11 patients. AHI was more elevated in SSA and FAP than in senile. NTproBNP 
was not different between the three types of amyloidosis. 
Conclusion: The prevalence of sleep-disordered breathing is high in cardiac 
amyloidosis population, with most syndromes having an obstructive pattern. Effect 
of SAS treatment should be investigated in this population.
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Iron overload does not potentiate doxorubicin cardiotoxicity in mice
Charles Guenancia (1), Ahmed Habbout (2), Stéphanie Delemasure Chalumeau (3), 
Eve Rigal (2), Luc Lorgis (1), Marianne Zeller (2), Yves Cottin (1), Luc 
Rochette (2), Catherine Vergely (2) 
(1) CHU Dijon, cardiologie, Dijon, France – (2) LPPCM, UMR 866 Inserm, 
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Background: Doxorubicin (DOX), an anthracycline used as an anticancer drug, 
is known to cause potentially life-threatening cardiotoxicity. Most of the proposed 
mechanisms involve oxidative stress. DOX forms a stable complex with iron. The 
mechanisms of interactions between iron metabolism and DOX-induced cardiotoxicity 
remain a matter of controversy.
Objectives: The role of iron in DOX cardiotoxicity was studied using a murine 
model of iron overloading (IO). We evaluated cardiac functional parameters, nitro-
oxidative stress levels and iron status.
Methods: For 3 weeks male C57BL/6 mice received a daily intraperitoneal 
injection of dextran iron (15 mg/kg/day) (n=16) or saline injection (n=16) and 
were then injected with a single dose of 6 mg/kg DOX or saline (8 animals in 
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Nuclear Factor of Activated T-cells (NFAT) and Myocyte Enhancer Factor-2 (MEF-2) 
using transient transfection and western blot.
In vitro, dox treatment (100nM) of neonatal rat cardiomyocytes for 24 hours 
resulted in an activation of ANF. Treatment with higher doses of dox leads to a 
decrease in the expression of remodelling markers. The transcription of MEF-2 is 
activated at 1 μM of doxorubicin but the transcriptional activity of NFAT decreases in 
a dose-dependent manner. In addition, we observed a strong reduction of Epac levels 
with doses as low as 10nM of Dox.
In vivo, echocardiography of mice treated with Dox by 3 iv injections reaching 
12mg/kg cumulative dose showed a tendency to dilated cardiomyopathy. At the 
molecular level, we observed a time-dependent regulation of Epac1, Epac2 and RhoA 
in cardiotoxicity induced by Dox. Moreover, phospholamban phosphorylation at the 
CamKII site but not the PKA site was decreased in dox-treated mice at 15 weeks 
suggesting an alteration of SERCA2a activity specifi cally mediated by Epac1. 
Our results indicate for the fi rst time an integrated time-course of Dox induced-
alteration in Epac signalling. 
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Electrocardiographic fi ndings in primary systemic amyloidosis, senile 
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Bordeneuve (3), Luc Hittinger (2), Thibaud Damy (2) 
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Henri Mondor, Fédération de cardiologie, Créteil, France – (3) CHU Henri 
Mondor, neurologie, Créteil, France
Objective: This study sought to determine the spectrum of electrocardiographic 
(ECG) abnormalities found in patients with primary systemic amyloidosis (AL), senile 
systemic amyloidosis (SSA) and Transthyretin-Related Amyloidosis (TTR) and to 
evaluate the prognostic implications. 
Methods: Between 2010 and 2012, 103 patients treated in the University Henri-
Mondor Hospital with cardiac amyloidosis were included. 32 patients with AL, 63 
patients with TTR and 11 patients with SSA. ECG were analysed regarding: rhythm, 
conduction, voltage, and ischaemic signs. 
Results: The mean age and men prevalence were respectively 62±15 and 64%. 
Atrial fi brillation was signifi cantly more frequent (p=0.005) in the SSA group (44%) 
compared to AL group (13%) and TTR group (7%). No signifi cant difference was found 
between the three groups when low voltage was defi ned according to the Klein criteria or 
defi ned as a voltage inferior to 1 mV in all precordial limbs. But when it was defi ned as a 
voltage <0. 5 mV in all limb leads it was found signifi cantly higher (p=0.006) in the AL 
population (36%) compared to the TTR (8%) and SSA (25%) groups. LV hypertrophy 
was rare in the three groups. No signifi cant difference was found concerning conduction 
disorders (p=0.064) and the presence of Q waves (61% AL, 51% TTR, 33% SSA, p=0.51) 
or reduced R wave height (7% AL, 20% TTR, 0% SSA, p=0.14). 
Conclusion: Electrocardiographic abnormalities are frequent in amyloidosis 
whatever the type.
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Doxorubicin cardiotoxicity: Altered calcium signaling in doxorubicin treated 
mice
Ana Llach Martinez, Marianne Mazevet, Philippe Mateo, Jean-Pierre Benitah, 
Eric Morel, Ana Maria Gomez
Inserm – Université Paris-Sud, UMR-S 769 – LabEx LERMIT, Châtenay-Malabry, 
France
Doxorubicin (Dox) is a highly effective cancer chemotherapeutic agent, but 
its clinical usefulness is limited because of its dose-dependent cardiotoxicity. Dox 
treatment can cause severe cardiomyopathy, as left ventricular dysfunction thus leading 
to fatal congestive heart failure (HF).
Among the pathophysiological mechanisms underlying dox-induced cardiotoxicity, 
dysregulations of calcium homeostasis and remodeling of the β-adrenergic signaling are 
involved but still need further investigation. Epac (exchange protein directly activated 
by cyclic AMP) could play an important role in the progression of dox-induced HF 
in regard to its signaling and recent role in cardiac remodeling.
Therefore, we investigated Ca2+ handling in a mice model treated with a total 
accumulated dose of 12 mg/kg of dox, 2, 6 and 15 weeks after last intravenous injection 
using patch-clamp, confocal imaging and western blot. Echocardiography of dox-treated 
mice showed a depressed contractile function at 15 weeks, correlated with a reduced 
and slower intracellular Ca2+ transients, increased incidence of Ca2+ sparks, and no 
signifi cant differences of the action potential duration and membrane capacitances. At the 
molecular level, among the proteins analyzed involved in excitation-contraction coupling, 
we observed a statistically signifi cant reduction of phospholamban phosphorylation at 
Thr-17. No effects on Ca2+ transients and sparks were observed when activating Epac 
signaling in dox-treated mice, which showed a reduced expression of Epac proteins.
Our results indicate for the fi rst time that Epac signaling is blunted after doxorubicin 
treatment and a decrease in phospholamban phosphorylation may underlie slower 
Ca2+ transients.
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Doxorubicin-induced cardiotoxicity: role of Epac signalling 
Marianne Mazevet (1), Anna Llach (1), Jean-Pierre Benitah (1), Philippe Matéo (1), 
Marie-Catherine Vozenin (2), Ana Maria Gomez (1), Eric Morel (1) 
(1) Inserm, U769, Chatenay Malabry, France – (2) Inserm, U1030, Villejuif, France
Doxorubicin (Dox), a widely used anticancer drug, can cause severe cardiac 
complications such as heart failure (HF). Among the pathophysiological mechanisms 
underlying dox-induced cardiotoxicity, remodelling of the β-adrenergic signalling 
appears to be involved but still need further investigation. Epac, an exchange protein 
directly activated by cyclic AMP, could play an important role in the progression of 
dox-induced HF in regard to the role of Rho-GTPases Rac1 and RhoA in dox side effects.
Therefore, we investigated the time- and dose-dependent effect of Dox both in vitro 
and in vivo on the transcriptional activity of cardiac remodelling and stress markers 
such as Atrial Natriuretic Factor (ANF), Serum Responsive Element-regulated c-fos 
(SRE) and muscle skeletal α-actin (SkM α-actin) and Epac’s downstream effectors: 
Table 1 – Abstract 400 – Evolution of BNP and echographic parameters from baseline to 12 months
Baseline 3 months 6 months 12 months
BNP, mean 1046 642 314* 443
Basal LVOTG gradient, mean 62.0 34.1* 37.3* 34.9*
Inducible LVTOG, mean 129.1 87.6* 72.5* 97.7*
E/A, mean 1.54 1.26* 1.41 1.45
E/Ea, mean 10.11 9.18 9.15 7.41
DT, mean 225 254 232 217
Footnotes: *values with signifi cant difference (p<0.05) with baseline value. BNP = B-type natriuretic peptide. LVOTG = Left ventricular outfl ow tract gradient.
© Elsevier Masson SAS. All rights reserved.
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ORAI3 contributes to a new voltage independent calcium entry that increases 
in hypertrophic ventricular rat myocyte
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Fauconnier (3), Anne-Marie Lompré (2) 
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Université Saint Joseph, Beyrouth, Liban – (2) Inserm UMRS 956, Université 
Pierre et Marie Curie, Paris, France – (3) Inserm U1046, Université Montpellier 1 
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Increasing amount of data suggest the implication of STIM1, TRPCs and ORAI1 
in mediating cardiac hypertrophy. In this work, we dissected the channel candidates 
accounting for the STIM1 dependent pro-hypertrophic sarcolemmal current previously 
depicted by our laboratory (Hulot et al. Circulation 2011). First we characterized the 
expression profi le of ORAIs proteins in both normal and hypertrophied ventricular 
myocytes isolated from abdominal aortic banded rats. ORAI1-3 are equally expressed in 
control and hypertrophic cardiac myocytes. We used a non-viral method to deliver cy3-
tagged siRNA to ventricular myocytes to knock-down the various channel candidates. 
The cardiac myocytes were isolated and the store-independent and store-dependent 
Ca2+ entry was measured on Fura-2 loaded cy3-labelled and control isolated cardiac 
myocytes. Whole cell patch-clamp technique was used to measure the currents. A 
mixture of ORAI1, 2 and 3 siRNAs completely inhibited both store-independent and 
store-dependent Ca2+ entry suggesting the implication of ORAIs. Surprisingly ORAI1 
siRNA activated Ca2+ entry, but this knock-down was associated with an up-regulation 
of ORAI3. ORAI3 siRNA completely blocked store-independent Ca2+ entry. As a 
regulator of pro-hypertrophic Ca2+ signaling, ORAI3 may represent a novel drug and 
genetic target for modulating pathologic calcineurin/NFAT signaling in the heart and 
treating cardiac hypertrophy and heart failure.
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Postnatal overfeeding in mice increase susceptibility to cardiotoxicity and 
oxidative stress induced by doxorubicin
Na Li, Charles Guenancia, Ahmed Habbout, Eve Rigal, Luc Rochette, Catherine 
Vergely
Université de Bourgogne, Inserm UMR866 LPPCM, Dijon, France
Doxorubicin (DOX), a commonly used anticancer drug, is known to induce serious 
cardiotoxicity that is believed to be mediated in part by oxidative stress. Obese patients 
and experimental animals were shown to have increased susceptibility to DOX-induced 
cardiotoxicity. Postnatal overfeeding (OF) in rodents induces a permanent moderate 
increase in body weight in adulthood, associated with cardio-metabolic alterations. 
Our study investigated the infl uence of moderate overweight on the sensitivity to 
DOX-induced cardiotoxicity and oxidative stress.
Immediately after birth, litters of C57BL/6 mice were either maintained at 10 
(normal-fed group, NF), or reduced to 3 in order to induce OF. At weaning, mice of 
both groups received a standard diet. At 4 months of age, mice were given a single 
intra-peritoneal injection of DOX (6 mg/kg). Cardiac function was followed using 
echocardiography. Myocardial mRNA expressions of antioxidant enzymes and of 
β-myosin heavy chain (β-MHC) were assessed 10 days after DOX injection. Oxidative 
stress was measured by electron spin resonance spectroscopy.
Four-months-old OF mice weighed 12% more than NF; nevertheless, their initial 
cardiac function was not modifi ed. A single injection of DOX induced a signifi cant 
decrease in left ventricular ejection fraction (LVEF) in both groups; however, the 
deterioration of cardiac function was higher in OF mice (49.9% vs 57%, p<0.05). In 
myocardial tissue, oxidative stress was increased (1.73±0.13 AU/mg vs 1.02±0.04 
AU/mg, p<0.01), and the expression of Cu/Zn- superoxide dismutase and catalase 
mRNA were signifi cantly decreased in OF mice (p<0.05). The expression of β-MHC 
in myocardial tissue was not signifi cantly augmented in OF mice.
Altogether, these results suggest that postnatal overfeeding, despite inducing a 
very small increase in body weight in adulthood, can potentiate doxorubicin-induced 
cardiotoxicity and oxidative stress. The exact mechanism of this vulnerability needs 
now to be investigated.
